Findings from the Australian Needle and Syringe Program (NSP) Survey 30-year National Data Report shows highly significant reductions in hepatitis C infections and high levels of treatment and cure among NSP clients. Nationally the proportion of respondents with active hepatitis C infection (HCV RNA positive) declined substantially, from 51% in 2015 to 8% in 2024.
In South Australia, the rate declined from 49% in 2015 to 6% in 2024. One SA Harm Reduction Peer Services worker, commenting on the decline in hepatitis C prevalence said, “This is an excellent result we should all be super proud of having a part in achieving. Still more work to do but that’s an incredible drop.”
